Regulatory

Nuvisan provides comprehensive regulatory support to guide your products through all phases of development. Our experienced regulatory team provides strategic advice for IND and NDA submissions, helping ensure all regulatory requirements are met with precision. We assist in the preparation of key regulatory documents, including quality, safety and efficacy data, to help ensure a smooth and efficient filing process.
 
Our CMC experts are skilled in designing optimal synthesis routes, developing innovative formulation and producing both GMP and non-GMP materials for clinical and non-clinical studies. With three GMP-certified sites, we offer the highest standards in analytical testing and documentation, including specifications, methods, reports and CoAs.
 
Nuvisan’s regulatory support also includes tailored documentation to support the scientific writing of your dossier, formulation reports and GMP certificates. With professional project management to monitor progress, we help ensure your IND filings are on track and aligned with industry standards, helping you accelerate your path to approval. 
Visualization of a biopharma companys workflow from lab to clinic

QP release

Nuvisan's team of EU qualified persons (QPs) provides expert oversight for all GMP operations. We provide QP services for investigational, compassionate use and commercial products, along with importation support, including third-country audits and import permit applications for global supply chains. 

learn more
Two printed documents are placed on a table for regulatory review

IND/NDA-enabling services

Nuvisan’s CMC experts help simplify drug development. Our sites offer the highest quality, while tailored solutions and expert project management services help accelerate IND submissions. Partner with us for seamless support from development to regulatory approval. Discover how we can advance your projects with our IND-enabling services online.

learn more

Frequently asked questions (FAQs)

  • What is a Qualified Person (QP)?
    A QP is a legally designated expert responsible for certifying that each batch of a medicinal product has been manufactured and tested in line with EU GMP and applicable regulatory requirements. QP certification is required before a product can be released to the EU market or supplied for use in clinical trials.
  • When is QP certification required in the EU?
    QP certification is required for every batch of medicinal product before release in the European Union (EU). This applies to both investigational medicinal products (IMPs) for clinical trials and commercially manufactured products. Certification must be performed by a QP in accordance with EU GMP requirements, particularly Annex 16. Without QP certification, a batch cannot be legally released to the market or supplied to clinical trial sites within the EU.
  • What does QP batch certification include?
    QP certification includes a review of the supply chain, manufacturing and quality documentation. This typically covers batch records, analytical results, deviations and compliance with the marketing authorisation or clinical trial application. A batch can only be released after this review has been completed satisfactorily.
  • Can you release IMPs and commercial batches?
    Yes. Nuvisan’s EU QPs have experience in certifying batches for both clinical trial use and commercial release.
     
  • What is required for EU batch release of non-EU products?
    For products manufactured outside the EU, additional steps are required before QP certification and release. These may include confirmation that the manufacturing site operates in compliance with EU GMP, or equivalent standards, review of complete batch documentation, and analytical testing within the EU where required. The QP must ensure that all relevant regulatory requirements are met, including importation controls and compliance with the applicable marketing authorisation or clinical trial application.
  • Do you perform GMP audits?
    Yes. We conduct GMP audits of manufacturers, suppliers and service providers. These audits support vendor qualification, assess compliance with regulatory requirements and contribute to inspection readiness.
  • Can you act as a single partner from manufacturing to release?
    Yes. We provide integrated support across manufacturing, clinical trial supply, quality assurance and QP release. This helps simplify coordination, reduce handovers and keep timelines on track.

Contact us

Nuvisan is committed to protecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Talk to us

talk icon
+49 731 9840 0 

Our locations

location icon

Neu-Ulm (headquarters)

Wegenerstrasse 13

89231 Neu-Ulm

Germany

Berlin

Muellerstrasse 178

13353 Berlin

Germany

Sophia Antipolis

2400 route des Colles

06410 Biot

France

Grafing

Am Feld 32

85567 Grafing

Germany

Waltrop

Im Wirrigen 25

45731 Waltrop

Germany

For concerns about pharmaceuticals or adverse drug-related events, contact us at: complaints@nuvisan.com